All In Biotech

Drug Trial Radar · NCT07921615

QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study

A Single-Center, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of QLS4131 in Combination With Isa-V-CHOP in Previously Untreated, HIV-Negative Patients With Plasmablastic Lymphoma (PBL)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 9, 2027

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, single-arm, open-label, phase II exploratory clinical study designed to evaluate the efficacy and safety of QLS4131 combined with the Isa-V-CHOP regimen in patients with treatment-naive, HIV-negative plasmablastic lymphoma. The study plans to enroll 10 patients. The study consists of a screening period, a study treatment period, and a follow-up period. The screening period will last up to 21 days. The study treatment period will run from C1D1 to the end of Cycle 6, or until early termination due to disease progression, toxicity, or other reasons. After the end of study treatment, patients will be followed for 24 months.

Conditions

  • Plasmablastic Lymphoma

Interventions

  • QLS4131 combined with Isa-V-CHOPDrug

    This study uses QLS4131 combined with the Isa-V-CHOP regimen for a total of 6 study cycles, with each cycle lasting 21 days. Vincristine and bortezomib will be administered at the adjusted doses and frequencies listed below; the doses will not be routinely escalated to the original high-intensity regimen merely because of good early tolerability. The treatment components are as follows: QLS4131 + Isa + V-CHOP regimen QLS4131: C1, 0.6 mg on d1, 3 mg on d4, 12 mg on d8; C2-6, 12 mg on d1 Isatuximab: 10 mg/kg in C1 on d1 and d8; C2-6, on d1 Bortezomib: 1.3 mg/m², SC, on d1 and d8 Cyclophosphamide: 750 mg/m², IV, on d1 Doxorubicin: 40-50 mg/m² or liposomal doxorubicin 30-40 mg/m², IV, on d1 Vincristine: 1.0 mg/m² (maximum dose 1.5 mg), IV, on d1 Prednisone: 60 mg/m² (maximum dose 100 mg), d1-5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response rate (CRR)Time frame: 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.